Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041212 | 0.84 | TRPV1 (0.63) | TRPV1 | |
| SCHEMBL4818598 | 0.81 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL5178056 | 0.80 | MAPT (0.42) | — | |
| SCHEMBL4812289 | 0.80 | — | — | |
| SCHEMBL5178052 | 0.80 | TRPV1 (0.39) | TRPV1MCHR1 | |
| SCHEMBL4006955 | 0.78 | MCHR1 (0.46) | TRPV1MCHR1 | |
| SCHEMBL4815366 | 0.78 | TRPV1 (0.75) | TRPV1 | |
| SCHEMBL1041450 | 0.77 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL1043192 | 0.74 | ADORA2A (0.40) | TRPV1MCHR1 | |
| SCHEMBL1042638 | 0.73 | TRPV1 (0.48) | TRPV1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1789413-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006031852-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885MCHR1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.